{"_default": {}, "triggers": {"1": {"rule_id": "balance_critical", "rule_name": "Solde critique", "priority": 1, "timestamp": "2026-01-21T19:18:05.142038", "context": {"recent_changes": [], "monitor_decision": {"should_trigger": false, "reason": "no_changes"}, "last_run_date": null, "current_balance": 0, "cash_runway_days": 180}, "saved_at": "2026-01-21T19:18:05.142193"}, "2": {"rule_id": "new_critical_invoice", "rule_name": "Facture critique d\u00e9tect\u00e9e", "priority": 1, "timestamp": "2026-01-21T19:25:40.822362", "context": {"recent_changes": [{"severity": "critical", "type": "new_row", "details": {"invoice_id": "F-DEMO-20260121-192440", "client_id": "CLI-LABORATOIR", "client_name": "Laboratoires BioPharm SAS", "invoice_date": "2025-09-01", "due_date": "2025-09-22", "amount": 850000.0, "status": "overdue", "payment_date": null, "days_overdue": 52, "risk_level": "critical"}}], "monitor_decision": {"should_trigger": true, "reason": "critical_change_detected (1 changes)"}, "last_run_date": "2026-01-21T19:18:40.791347", "current_balance": 4545500, "cash_runway_days": 165}, "saved_at": "2026-01-21T19:25:40.823224"}}, "runs": {"1": {"run_id": "1e8e3b48-f143-4196-ad4e-70347184a566", "timestamp": "2026-01-21T19:18:40.791347", "trigger_reason": "Solde critique", "deliverables": {"treasury": {"current_balance": 4545500, "as_of_date": "2026-01-21", "total_inflows_mtd": 2515000, "total_outflows_mtd": 575500, "pending_client_payments": 8250000, "pending_supplier_payments": 278000, "cash_runway_days": 165, "status": "safe"}, "forecasts": {"4_weeks": {"horizon_weeks": 4, "horizon_label": "Court terme (4 sem.)", "start_balance": 4545500, "projected_inflows": 2867550.0, "projected_outflows": 0.0, "end_balance": 7413050.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7413050.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}]}, "8_weeks": {"horizon_weeks": 8, "horizon_label": "Moyen terme (8 sem.)", "start_balance": 4545500, "projected_inflows": 3361800.0, "projected_outflows": 0.0, "end_balance": 7907300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7907300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}]}, "13_weeks": {"horizon_weeks": 13, "horizon_label": "Long terme (13 sem.)", "start_balance": 4545500, "projected_inflows": 3534800.0, "projected_outflows": 0.0, "end_balance": 8080300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 8080300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}, {"week": 9, "start_date": "2026-03-18", "end_date": "2026-03-25", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7907300.0}, {"week": 10, "start_date": "2026-03-25", "end_date": "2026-04-01", "inflows": 119000.0, "outflows": 0.0, "net_flow": 119000.0, "end_balance": 8026300.0}, {"week": 11, "start_date": "2026-04-01", "end_date": "2026-04-08", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 12, "start_date": "2026-04-08", "end_date": "2026-04-15", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 13, "start_date": "2026-04-15", "end_date": "2026-04-22", "inflows": 54000.0, "outflows": 0.0, "net_flow": 54000.0, "end_balance": 8080300.0}]}}, "risks": [{"id": "RISK-005", "category": "client_payment", "severity": "critical", "score": 93, "title": "Retard paiement Groupe Pharmaceutique Nord", "description": "Facture F-2025-061 en retard de 93 jours", "amount_at_risk": 525000, "due_date": "2025-10-20", "entity_id": "CLI-009", "entity_name": "Groupe Pharmaceutique Nord", "days_overdue": 93, "recommended_action": "Relancer Groupe Pharmaceutique Nord - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-007", "category": "client_payment", "severity": "high", "score": 86, "title": "Retard paiement Institut Recherche Appliqu\u00e9e", "description": "Facture F-2025-078 en retard de 81 jours", "amount_at_risk": 640000, "due_date": "2025-11-01", "entity_id": "CLI-013", "entity_name": "Institut Recherche Appliqu\u00e9e", "days_overdue": 81, "recommended_action": "Relancer Institut Recherche Appliqu\u00e9e - priorit\u00e9 haute"}, {"id": "RISK-002", "category": "client_payment", "severity": "high", "score": 80, "title": "Retard paiement Groupe Innov Sant\u00e9", "description": "Facture F-2026-003 en retard de 68 jours", "amount_at_risk": 615000, "due_date": "2025-11-14", "entity_id": "CLI-003", "entity_name": "Groupe Innov Sant\u00e9", "days_overdue": 68, "recommended_action": "Relancer Groupe Innov Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-012", "category": "supplier", "severity": "high", "score": 75, "title": "Facture fournisseur impay\u00e9e - Cabinet Audit & Contr\u00f4le", "description": "Facture SUPP-2026-002 en retard de 32 jours", "amount_at_risk": 45000, "due_date": "2025-12-20", "entity_id": "SUPP-002", "entity_name": "Cabinet Audit & Contr\u00f4le", "days_overdue": 32, "recommended_action": "R\u00e9gulariser le paiement de Cabinet Audit & Contr\u00f4le"}, {"id": "RISK-008", "category": "client_payment", "severity": "high", "score": 72, "title": "Retard paiement PME Innovation Sant\u00e9", "description": "Facture F-2025-085 en retard de 51 jours", "amount_at_risk": 380000, "due_date": "2025-12-01", "entity_id": "CLI-016", "entity_name": "PME Innovation Sant\u00e9", "days_overdue": 51, "recommended_action": "Relancer PME Innovation Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-009", "category": "client_payment", "severity": "medium", "score": 68, "title": "Retard paiement Groupe Export International", "description": "Facture F-2025-092 en retard de 42 jours", "amount_at_risk": 560000, "due_date": "2025-12-10", "entity_id": "CLI-019", "entity_name": "Groupe Export International", "days_overdue": 42, "recommended_action": "Relancer Groupe Export International - priorit\u00e9 haute"}, {"id": "RISK-004", "category": "client_payment", "severity": "medium", "score": 64, "title": "Retard paiement Startup DeepTech IA", "description": "Facture F-2026-007 en retard de 37 jours", "amount_at_risk": 165000, "due_date": "2025-12-15", "entity_id": "CLI-007", "entity_name": "Startup DeepTech IA", "days_overdue": 37, "recommended_action": "Relancer Startup DeepTech IA - priorit\u00e9 haute"}, {"id": "RISK-011", "category": "client_payment", "severity": "medium", "score": 62, "title": "Retard paiement Groupe Industrie 4.0", "description": "Facture F-2025-105 en retard de 34 jours", "amount_at_risk": 490000, "due_date": "2025-12-18", "entity_id": "CLI-024", "entity_name": "Groupe Industrie 4.0", "days_overdue": 34, "recommended_action": "Relancer Groupe Industrie 4.0 - priorit\u00e9 haute"}, {"id": "RISK-001", "category": "client_payment", "severity": "medium", "score": 61, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-2026-001 en retard de 32 jours", "amount_at_risk": 485000, "due_date": "2025-12-20", "entity_id": "CLI-001", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 32, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-010", "category": "client_payment", "severity": "medium", "score": 58, "title": "Retard paiement ETI Manufacturing", "description": "Facture F-2025-098 en retard de 27 jours", "amount_at_risk": 315000, "due_date": "2025-12-25", "entity_id": "CLI-021", "entity_name": "ETI Manufacturing", "days_overdue": 27, "recommended_action": "Relancer ETI Manufacturing - priorit\u00e9 haute"}, {"id": "RISK-003", "category": "client_payment", "severity": "medium", "score": 56, "title": "Retard paiement Conseil Strat\u00e9gie & Finance", "description": "Facture F-2026-006 en retard de 24 jours", "amount_at_risk": 125000, "due_date": "2025-12-28", "entity_id": "CLI-006", "entity_name": "Conseil Strat\u00e9gie & Finance", "days_overdue": 24, "recommended_action": "Relancer Conseil Strat\u00e9gie & Finance - priorit\u00e9 haute"}, {"id": "RISK-006", "category": "client_payment", "severity": "medium", "score": 54, "title": "Retard paiement FinTech Solutions Europe", "description": "Facture F-2025-050 en retard de 21 jours", "amount_at_risk": 195000, "due_date": "2025-12-31", "entity_id": "CLI-010", "entity_name": "FinTech Solutions Europe", "days_overdue": 21, "recommended_action": "Relancer FinTech Solutions Europe - priorit\u00e9 haute"}], "actions": [{"id": "ACTION-001", "priority": 1, "category": "recouvrement", "action": "Appeler Groupe Pharmaceutique Nord pour obtenir un engagement de paiement sous 48h", "expected_impact": 525000, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-005"]}, {"id": "ACTION-002", "priority": 2, "category": "recouvrement", "action": "Campagne de relance pour 3 factures en retard", "expected_impact": 981000.0, "deadline": "2026-02-04", "effort": "medium", "risk_ids": ["RISK-007", "RISK-002", "RISK-008"]}, {"id": "ACTION-003", "priority": 3, "category": "fournisseurs", "action": "R\u00e9gulariser 1 factures fournisseurs en retard", "expected_impact": 45000, "deadline": "2026-01-28", "effort": "low", "risk_ids": ["RISK-012"]}], "dg_note": "# Note DAF - Situation Tr\u00e9sorerie et Risques\n**Date:** Aujourd'hui  \n**Objet:** Point de situation tr\u00e9sorerie et risques associ\u00e9s\n\n## Situation actuelle\nLa position de tr\u00e9sorerie de Demo PME-ETI se situe \u00e0 4,545M\u20ac, offrant une visibilit\u00e9 de 165 jours d'exploitation. Le niveau d'encours clients s'\u00e9l\u00e8ve \u00e0 8,25M\u20ac, contrastant avec un encours fournisseurs ma\u00eetris\u00e9 de 278K\u20ac.\n\n## Points de vigilance\n* Un montant total de 4,54M\u20ac est actuellement consid\u00e9r\u00e9 \u00e0 risque, repr\u00e9sentant:\n  - 1 risque critique\n  - 4 risques \u00e9lev\u00e9s\n* Le principal point d'attention concerne le Groupe Pharmaceutique Nord avec un retard de paiement de 525K\u20ac\n\n## Impact et risques\n* La situation de tr\u00e9sorerie est actuellement consid\u00e9r\u00e9e comme s\u00e9curis\u00e9e (\"safe\")\n* Toutefois, le d\u00e9s\u00e9quilibre significatif entre encours clients (8,25M\u20ac) et fournisseurs (278K\u20ac) n\u00e9cessite une surveillance accrue\n* Le montant total \u00e0 risque (4,54M\u20ac) repr\u00e9sente une part significative de notre tr\u00e9sorerie actuelle\n\n## Recommandations\n1. **Actions imm\u00e9diates:**\n   - Engagement d'une action directe aupr\u00e8s du Groupe Pharmaceutique Nord pour obtenir un engagement ferme de paiement sous 48h\n   - Lancement d'une campagne de relance cibl\u00e9e sur les 3 factures identifi\u00e9es en retard\n\n2. **Suivi:**\n   - Mise en place d'un reporting quotidien sur l'avancement des relances\n   - Point hebdomadaire sur l'\u00e9volution des encours clients \u00e0 risque\n\nUne actualisation de la situation sera communiqu\u00e9e \u00e0 la Direction G\u00e9n\u00e9rale d\u00e8s obtention des engagements de paiement du Groupe Pharmaceutique Nord.", "risk_explanations": {"RISK-005": "Le retard de paiement de 525,000\u20ac du Groupe Pharmaceutique Nord repr\u00e9sente un risque critique car il d\u00e9passe notre seuil de tol\u00e9rance habituel de 90 jours, mettant en p\u00e9ril notre relation commerciale avec ce client strat\u00e9gique. Bien que notre tr\u00e9sorerie actuelle soit confortable (4.5M\u20ac), le montant en retard \u00e9quivaut pr\u00e9cis\u00e9ment \u00e0 notre seuil critique de tr\u00e9sorerie (500K\u20ac), ce qui pourrait compromettre notre capacit\u00e9 \u00e0 faire face \u00e0 des impr\u00e9vus. Une action imm\u00e9diate de relance au niveau Direction est recommand\u00e9e, avec potentiellement la mise en place d'un \u00e9ch\u00e9ancier de paiement."}, "action_justification": "La priorisation propos\u00e9e est logique pour les raisons suivantes :\n\nP1 - Groupe Pharmaceutique Nord (525k\u20ac) : Action prioritaire car elle combine un fort impact financier imm\u00e9diat avec un effort minimal (un simple appel). Le recouvrement rapide sous 48h permettra d'am\u00e9liorer rapidement la tr\u00e9sorerie.\n\nP2 - Campagne de relance (981k\u20ac) : Bien que l'impact soit plus \u00e9lev\u00e9 que P1, cette action n\u00e9cessite plus de temps et d'efforts pour traiter 3 factures distinctes. Le retour sur investissement est plus dilu\u00e9 dans le temps.\n\nP3 - R\u00e9gularisation fournisseur (45k\u20ac) : Impact financier plus faible et moins urgent que les actions de recouvrement client. Le risque de tension avec le fournisseur reste limit\u00e9 vu le montant.\n\nCette priorisation optimise le ratio impact/effort en privil\u00e9giant les actions rapides \u00e0 fort impact sur la tr\u00e9sorerie."}, "summary": {"balance": 4545500, "runway_days": 165, "risks_count": 12, "actions_count": 3}}, "2": {"run_id": "22c995b6-299a-4ec2-80f8-64f2fe11ad2c", "timestamp": "2026-01-21T19:26:21.604859", "trigger_reason": "Facture critique d\u00e9tect\u00e9e", "deliverables": {"treasury": {"current_balance": 4545500, "as_of_date": "2026-01-21", "total_inflows_mtd": 2515000, "total_outflows_mtd": 575500, "pending_client_payments": 9100000.0, "pending_supplier_payments": 278000, "cash_runway_days": 165, "status": "safe"}, "forecasts": {"4_weeks": {"horizon_weeks": 4, "horizon_label": "Court terme (4 sem.)", "start_balance": 4545500, "projected_inflows": 2867550.0, "projected_outflows": 0.0, "end_balance": 7413050.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7413050.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}]}, "8_weeks": {"horizon_weeks": 8, "horizon_label": "Moyen terme (8 sem.)", "start_balance": 4545500, "projected_inflows": 3361800.0, "projected_outflows": 0.0, "end_balance": 7907300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 7907300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}]}, "13_weeks": {"horizon_weeks": 13, "horizon_label": "Long terme (13 sem.)", "start_balance": 4545500, "projected_inflows": 3534800.0, "projected_outflows": 0.0, "end_balance": 8080300.0, "min_balance": 4545500, "min_balance_date": "2026-01-21", "probability_weighted_balance": 8080300.0, "status": "safe", "weekly_breakdown": [{"week": 1, "start_date": "2026-01-21", "end_date": "2026-01-28", "inflows": 957550.0, "outflows": 0.0, "net_flow": 957550.0, "end_balance": 5503050.0}, {"week": 2, "start_date": "2026-01-28", "end_date": "2026-02-04", "inflows": 510750.0, "outflows": 0.0, "net_flow": 510750.0, "end_balance": 6013800.0}, {"week": 3, "start_date": "2026-02-04", "end_date": "2026-02-11", "inflows": 631500.0, "outflows": 0.0, "net_flow": 631500.0, "end_balance": 6645300.0}, {"week": 4, "start_date": "2026-02-11", "end_date": "2026-02-18", "inflows": 767750.0, "outflows": 0.0, "net_flow": 767750.0, "end_balance": 7413050.0}, {"week": 5, "start_date": "2026-02-18", "end_date": "2026-02-25", "inflows": 122500.0, "outflows": 0.0, "net_flow": 122500.0, "end_balance": 7535550.0}, {"week": 6, "start_date": "2026-02-25", "end_date": "2026-03-04", "inflows": 177750.0, "outflows": 0.0, "net_flow": 177750.0, "end_balance": 7713300.0}, {"week": 7, "start_date": "2026-03-04", "end_date": "2026-03-11", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7713300.0}, {"week": 8, "start_date": "2026-03-11", "end_date": "2026-03-18", "inflows": 194000.0, "outflows": 0.0, "net_flow": 194000.0, "end_balance": 7907300.0}, {"week": 9, "start_date": "2026-03-18", "end_date": "2026-03-25", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 7907300.0}, {"week": 10, "start_date": "2026-03-25", "end_date": "2026-04-01", "inflows": 119000.0, "outflows": 0.0, "net_flow": 119000.0, "end_balance": 8026300.0}, {"week": 11, "start_date": "2026-04-01", "end_date": "2026-04-08", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 12, "start_date": "2026-04-08", "end_date": "2026-04-15", "inflows": 0.0, "outflows": 0.0, "net_flow": 0.0, "end_balance": 8026300.0}, {"week": 13, "start_date": "2026-04-15", "end_date": "2026-04-22", "inflows": 54000.0, "outflows": 0.0, "net_flow": 54000.0, "end_balance": 8080300.0}]}}, "risks": [{"id": "RISK-012", "category": "client_payment", "severity": "critical", "score": 100, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-DEMO-20260121-192440 en retard de 121 jours", "amount_at_risk": 850000.0, "due_date": "2025-09-22", "entity_id": "CLI-LABORATOIR", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 121, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-005", "category": "client_payment", "severity": "critical", "score": 93, "title": "Retard paiement Groupe Pharmaceutique Nord", "description": "Facture F-2025-061 en retard de 93 jours", "amount_at_risk": 525000.0, "due_date": "2025-10-20", "entity_id": "CLI-009", "entity_name": "Groupe Pharmaceutique Nord", "days_overdue": 93, "recommended_action": "Relancer Groupe Pharmaceutique Nord - priorit\u00e9 imm\u00e9diate"}, {"id": "RISK-007", "category": "client_payment", "severity": "high", "score": 86, "title": "Retard paiement Institut Recherche Appliqu\u00e9e", "description": "Facture F-2025-078 en retard de 81 jours", "amount_at_risk": 640000.0, "due_date": "2025-11-01", "entity_id": "CLI-013", "entity_name": "Institut Recherche Appliqu\u00e9e", "days_overdue": 81, "recommended_action": "Relancer Institut Recherche Appliqu\u00e9e - priorit\u00e9 haute"}, {"id": "RISK-002", "category": "client_payment", "severity": "high", "score": 80, "title": "Retard paiement Groupe Innov Sant\u00e9", "description": "Facture F-2026-003 en retard de 68 jours", "amount_at_risk": 615000.0, "due_date": "2025-11-14", "entity_id": "CLI-003", "entity_name": "Groupe Innov Sant\u00e9", "days_overdue": 68, "recommended_action": "Relancer Groupe Innov Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-013", "category": "supplier", "severity": "high", "score": 75, "title": "Facture fournisseur impay\u00e9e - Cabinet Audit & Contr\u00f4le", "description": "Facture SUPP-2026-002 en retard de 32 jours", "amount_at_risk": 45000, "due_date": "2025-12-20", "entity_id": "SUPP-002", "entity_name": "Cabinet Audit & Contr\u00f4le", "days_overdue": 32, "recommended_action": "R\u00e9gulariser le paiement de Cabinet Audit & Contr\u00f4le"}, {"id": "RISK-008", "category": "client_payment", "severity": "high", "score": 72, "title": "Retard paiement PME Innovation Sant\u00e9", "description": "Facture F-2025-085 en retard de 51 jours", "amount_at_risk": 380000.0, "due_date": "2025-12-01", "entity_id": "CLI-016", "entity_name": "PME Innovation Sant\u00e9", "days_overdue": 51, "recommended_action": "Relancer PME Innovation Sant\u00e9 - priorit\u00e9 haute"}, {"id": "RISK-009", "category": "client_payment", "severity": "medium", "score": 68, "title": "Retard paiement Groupe Export International", "description": "Facture F-2025-092 en retard de 42 jours", "amount_at_risk": 560000.0, "due_date": "2025-12-10", "entity_id": "CLI-019", "entity_name": "Groupe Export International", "days_overdue": 42, "recommended_action": "Relancer Groupe Export International - priorit\u00e9 haute"}, {"id": "RISK-004", "category": "client_payment", "severity": "medium", "score": 64, "title": "Retard paiement Startup DeepTech IA", "description": "Facture F-2026-007 en retard de 37 jours", "amount_at_risk": 165000.0, "due_date": "2025-12-15", "entity_id": "CLI-007", "entity_name": "Startup DeepTech IA", "days_overdue": 37, "recommended_action": "Relancer Startup DeepTech IA - priorit\u00e9 haute"}, {"id": "RISK-011", "category": "client_payment", "severity": "medium", "score": 62, "title": "Retard paiement Groupe Industrie 4.0", "description": "Facture F-2025-105 en retard de 34 jours", "amount_at_risk": 490000.0, "due_date": "2025-12-18", "entity_id": "CLI-024", "entity_name": "Groupe Industrie 4.0", "days_overdue": 34, "recommended_action": "Relancer Groupe Industrie 4.0 - priorit\u00e9 haute"}, {"id": "RISK-001", "category": "client_payment", "severity": "medium", "score": 61, "title": "Retard paiement Laboratoires BioPharm SAS", "description": "Facture F-2026-001 en retard de 32 jours", "amount_at_risk": 485000.0, "due_date": "2025-12-20", "entity_id": "CLI-001", "entity_name": "Laboratoires BioPharm SAS", "days_overdue": 32, "recommended_action": "Relancer Laboratoires BioPharm SAS - priorit\u00e9 haute"}, {"id": "RISK-010", "category": "client_payment", "severity": "medium", "score": 58, "title": "Retard paiement ETI Manufacturing", "description": "Facture F-2025-098 en retard de 27 jours", "amount_at_risk": 315000.0, "due_date": "2025-12-25", "entity_id": "CLI-021", "entity_name": "ETI Manufacturing", "days_overdue": 27, "recommended_action": "Relancer ETI Manufacturing - priorit\u00e9 haute"}, {"id": "RISK-003", "category": "client_payment", "severity": "medium", "score": 56, "title": "Retard paiement Conseil Strat\u00e9gie & Finance", "description": "Facture F-2026-006 en retard de 24 jours", "amount_at_risk": 125000.0, "due_date": "2025-12-28", "entity_id": "CLI-006", "entity_name": "Conseil Strat\u00e9gie & Finance", "days_overdue": 24, "recommended_action": "Relancer Conseil Strat\u00e9gie & Finance - priorit\u00e9 haute"}, {"id": "RISK-006", "category": "client_payment", "severity": "medium", "score": 54, "title": "Retard paiement FinTech Solutions Europe", "description": "Facture F-2025-050 en retard de 21 jours", "amount_at_risk": 195000.0, "due_date": "2025-12-31", "entity_id": "CLI-010", "entity_name": "FinTech Solutions Europe", "days_overdue": 21, "recommended_action": "Relancer FinTech Solutions Europe - priorit\u00e9 haute"}], "actions": [{"id": "ACTION-001", "priority": 1, "category": "recouvrement", "action": "Appeler Laboratoires BioPharm SAS pour obtenir un engagement de paiement sous 48h", "expected_impact": 850000.0, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-012"]}, {"id": "ACTION-002", "priority": 1, "category": "recouvrement", "action": "Appeler Groupe Pharmaceutique Nord pour obtenir un engagement de paiement sous 48h", "expected_impact": 525000.0, "deadline": "2026-01-23", "effort": "low", "risk_ids": ["RISK-005"]}, {"id": "ACTION-003", "priority": 2, "category": "recouvrement", "action": "Campagne de relance pour 3 factures en retard", "expected_impact": 981000.0, "deadline": "2026-02-04", "effort": "medium", "risk_ids": ["RISK-007", "RISK-002", "RISK-008"]}, {"id": "ACTION-004", "priority": 3, "category": "fournisseurs", "action": "R\u00e9gulariser 1 factures fournisseurs en retard", "expected_impact": 45000, "deadline": "2026-01-28", "effort": "low", "risk_ids": ["RISK-013"]}], "dg_note": "# Note Direction Financi\u00e8re\n**Date:** Aujourd'hui  \n**Objet:** Point de situation tr\u00e9sorerie et risques associ\u00e9s\n\n## Situation actuelle\nLa position de tr\u00e9sorerie de Demo PME-ETI pr\u00e9sente un solde de 4,545,500\u20ac, offrant une visibilit\u00e9 de 165 jours d'exploitation. Le niveau d'encours clients s'\u00e9l\u00e8ve \u00e0 9,100,000\u20ac, contre un encours fournisseurs ma\u00eetris\u00e9 de 278,000\u20ac.\n\n## Points de vigilance\nLa situation financi\u00e8re n\u00e9cessite une attention particuli\u00e8re sur les \u00e9l\u00e9ments suivants :\n\n* Identification de 2 risques critiques et 4 risques \u00e9lev\u00e9s\n* Montant total expos\u00e9 : 5,390,000\u20ac, soit plus que la tr\u00e9sorerie disponible\n* Deux retards de paiement majeurs :\n  - Laboratoires BioPharm SAS : 850,000\u20ac\n  - Groupe Pharmaceutique Nord : 525,000\u20ac\n\n## Recommandations\nActions imm\u00e9diates \u00e0 mettre en \u0153uvre :\n\n1. **Actions prioritaires sur les risques critiques**\n   * Contact direct avec Laboratoires BioPharm SAS pour obtenir un engagement ferme de r\u00e8glement sous 48h\n   * M\u00eame d\u00e9marche aupr\u00e8s du Groupe Pharmaceutique Nord\n\n2. **Gestion du portefeuille clients**\n   * Lancement d'une campagne de relance cibl\u00e9e sur 3 factures identifi\u00e9es en retard\n   * Suivi quotidien des engagements de paiement\n\n3. **Pilotage renforc\u00e9**\n   * Mise en place d'un reporting quotidien sur l'\u00e9volution des encaissements critiques\n   * Point hebdomadaire sur l'avancement des actions de recouvrement\n\nLa situation reste sous contr\u00f4le mais n\u00e9cessite une action rapide sur les retards de paiement significatifs pour s\u00e9curiser la position de tr\u00e9sorerie.", "risk_explanations": {"RISK-012": "Le retard de paiement de 850k\u20ac des Laboratoires BioPharm SAS est critique car il d\u00e9passe largement le d\u00e9lai standard de recouvrement (121 jours), ce qui peut signaler des difficult\u00e9s financi\u00e8res chez ce client. Bien que notre tr\u00e9sorerie actuelle soit confortable \u00e0 4,5M\u20ac, l'anciennet\u00e9 de cette cr\u00e9ance augmente significativement le risque d'impay\u00e9 et n\u00e9cessite une action imm\u00e9diate de relance, potentiellement via notre service juridique. Je recommande d'engager une proc\u00e9dure de recouvrement contentieux si aucun \u00e9ch\u00e9ancier n'est mis en place sous 48h.", "RISK-005": "Le retard de paiement de 525,000\u20ac du Groupe Pharmaceutique Nord est critique car il d\u00e9passe largement le d\u00e9lai standard de recouvrement (93 jours) et repr\u00e9sente plus de 11% de notre tr\u00e9sorerie actuelle. Bien que notre position de tr\u00e9sorerie soit actuellement confortable, le montant en jeu \u00e9quivaut \u00e0 notre seuil critique de fonctionnement (500,000\u20ac), ce qui pourrait compromettre notre capacit\u00e9 \u00e0 honorer nos propres engagements si d'autres retards venaient s'y ajouter. Une action de recouvrement imm\u00e9diate est n\u00e9cessaire, possiblement via notre service contentieux."}, "action_justification": "La priorisation propos\u00e9e est optimale pour les raisons suivantes :\n\nP1 - Les appels aux Laboratoires BioPharm (850k\u20ac) et Groupe Pharma Nord (525k\u20ac) sont prioritaires car ils repr\u00e9sentent des montants significatifs avec une action imm\u00e9diate possible. L'engagement sous 48h permet de s\u00e9curiser rapidement 1,375M\u20ac de tr\u00e9sorerie.\n\nP2 - La campagne de relance (981k\u20ac) est en P2 car, bien que le montant soit important, l'action est plus diffuse (3 factures) et le retour moins imm\u00e9diat qu'un engagement direct des deux gros clients en P1.\n\nP3 - La r\u00e9gularisation fournisseur (45k\u20ac) est moins urgente car le montant est faible compar\u00e9 aux autres actions et l'impact sur les risques critiques/\u00e9lev\u00e9s semble limit\u00e9.\n\nCette priorisation permet d'adresser rapidement les plus gros enjeux financiers (1,375M\u20ac) avec un effort concentr\u00e9 sur deux actions \u00e0 fort impact imm\u00e9diat."}, "summary": {"balance": 4545500, "runway_days": 165, "risks_count": 13, "actions_count": 4}}}}